Jefferies on Dyne Therapeutics (DYN): 'We remain 70-80%+ confident in an AA approval by Q1:27'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $50.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst comments "At ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
